HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
about
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsMaximizing the Therapeutic Potential of HSP90 InhibitorsNoise-Driven Phenotypic Heterogeneity with Finite Correlation Time in Clonal PopulationsHSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cellsCombined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Heat Shock Protein 90 Associates with the Per-Arnt-Sim Domain of Heme-free Soluble Guanylate Cyclase: IMplications for Enzyme Maturation.Selection Transforms the Landscape of Genetic Variation Interacting with Hsp90.Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.Heat Shock Proteins Promote Cancer: It's a Protection RacketNon-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.Antileukemic Scalarane Sesterterpenoids and Meroditerpenoid from Carteriospongia (Phyllospongia) sp., Induce Apoptosis via Dual Inhibitory Effects on Topoisomerase II and Hsp90.Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature.Molecular mechanism of thermosensory function of human heat shock transcription factor Hsf1.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.HSP90 Shapes the Consequences of Human Genetic Variation.Blocking the survival of the nastiest by HSP90 inhibitionHost proteostasis modulates influenza evolution.HSP90 Inhibition and Cellular Stress Elicits Phenotypic Plasticity in Hematopoietic Differentiation.Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial.Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation.Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens.Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine.Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.Increased proteomic complexity in Drosophila hybrids during development.Molecular genetics: Chaperone protein gets personal.Mechanisms for estrogen receptor expression in human cancerExploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
P2860
Q26782449-5031B0EE-23DE-429B-A76F-7FBB75841F84Q26798318-EE5ECA72-9D6B-4567-B838-C33271B5A8DAQ28546735-E0A14907-E116-4396-8A73-AA679D1BAB90Q33823200-9A137F32-68B8-4F35-ABEF-D658B7D0BA97Q35930811-D8EB9CB2-C19F-40F1-9E90-9DCB3CFC95D3Q36065122-F2C3E1F6-3A1E-448D-9F1B-4E832FBA8799Q36170641-F23EBFB5-9016-42E3-AD88-206571BAA37DQ36655158-60689A27-EE1E-4B31-AED4-C1621D2977F0Q37013952-E8D00ACC-D623-47E1-98BE-87084CDF2E50Q37278393-FD0259A1-5878-4741-8E2D-A040242E1E43Q37379572-7DDA6413-A61F-40CA-A23E-3E4B300F9210Q38691228-8E895CEF-9D62-4EA6-A32B-92654670783EQ38729074-DB714243-1DF5-4E43-9C45-FD199F6749ADQ38734451-5DD06546-E9C6-44EB-8A5A-9C3C9F799B5DQ38737681-B162EE05-FCC4-44FF-B7BC-A55B9493EAB6Q38953212-B88F5A4C-B9B3-4433-86BD-8B777D154980Q39995934-AEB9CDC8-2BDA-4556-9817-530F22E438EDQ41671786-C51B8CC6-B2A0-4BED-94EA-A97DD7EF6B2AQ42380877-7B3D12DB-1E72-4AE6-A558-51BC187F9979Q42651973-57D517DA-8E77-4AE3-B511-980C21318EE0Q45874458-CC10239F-1567-42F7-9740-377E053BCAAAQ47135858-FE0E7CA7-F9BE-45EF-9485-171118B7BB7CQ47362444-02240715-D20A-4DFD-8EF6-825B88D85978Q48069881-68C20677-F7B0-430C-9E89-C3B26E0A1FC3Q48118580-AA523455-C93D-4A4F-9958-485CC9BF8666Q49255117-5A9687BC-5FB4-417C-978B-0D2275BB8AECQ49752343-4EECCA07-C492-490D-AB64-4D318262737BQ51046987-9CE17312-B209-4138-9558-CC3F55EC176DQ58718563-48BDC4DF-81DB-44D7-B2C1-8128513A5B0AQ58802587-272843E2-9A5B-4FFA-B60B-B2A96C59C480
P2860
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@ast
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@en
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@nl
type
label
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@ast
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@en
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@nl
prefLabel
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@ast
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@en
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@nl
P2093
P2860
P356
P1476
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.
@en
P2093
David A Proia
Marc L Mendillo
Nancy U Lin
Sandro Santagata
P2860
P304
18297-18302
P356
10.1073/PNAS.1421323111
P407
P577
2014-12-08T00:00:00Z